SCI REP:肺癌DC细胞的STAT3以及NF-κB通路抑制

2017-03-29 MedSci MedSci原创

肺癌是世界范围内最常见的恶性肿瘤之一,超过80%为非小细胞肺癌。DC细胞对于继发免疫反应至关重要,在肿瘤发展过程中DC细胞的抗原识别呈递功能受限,肿瘤诱导DC细胞耐受被认为是肿瘤进展侵袭的关键因素,但是肿瘤细胞诱导DC细胞功能缺损的机制尚不清楚。

肺癌是世界范围内最常见的恶性肿瘤之一,超过80%为非小细胞肺癌。DC细胞对于继发免疫反应至关重要,在肿瘤发展过程中DC细胞的抗原识别呈递功能受限,肿瘤诱导DC细胞耐受被认为是肿瘤进展侵袭的关键因素,但是肿瘤细胞诱导DC细胞功能缺损的机制尚不清楚。

SCI REP近期发表了一篇文章研究了肺癌DC细胞功能受限的机制。在体外实验模型中,作者使用多个非小细胞肺癌患者的血清培养肿瘤诱导DC细胞。实验结果发现肿瘤诱导的单核细胞来源DC细胞存在系统性缺陷。转录组学分析主要功能基因的表达情况发现与正常细胞相比,肿瘤诱导DC细胞的MHCⅡ、细胞因子、趋化因子以及共刺激分子表达明显改变。进一步研究证实肿瘤血清中NF-κB通路和STAT3通路同时受到抑制,表明NF-κB通路和STAT3通路受限可能是肿瘤中DC细胞功能下降的主要原因。

对肿瘤诱导DC细胞分子机制的研究有助于理解DC细胞功能缺损导致的肿瘤免疫逃逸,使控制抑制信号传递以及增强对肿瘤的免疫监控成为可能。

原始出处:
Rui Li,Fang-Fang,et al.STAT3 and NK-κB are simultaneously Suppresses in Dendritic Cells in Lung Cancer.SCI REP.28 March 2017 doi:10.1038/srep45395

本位系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1348956, encodeId=6713134895620, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Mar 31 03:39:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534043, encodeId=a15e153404383, content=<a href='/topic/show?id=6ea85e6117' target=_blank style='color:#2F92EE;'>#DC细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5761, encryptionId=6ea85e6117, topicName=DC细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=067412523287, createdName=zhangyxzsh, createdTime=Fri Mar 31 03:39:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183577, encodeId=da0e1835e7b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Wed Mar 29 19:33:51 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183564, encodeId=85811835640f, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Mar 29 19:28:48 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-03-31 李研东
  2. [GetPortalCommentsPageByObjectIdResponse(id=1348956, encodeId=6713134895620, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Mar 31 03:39:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534043, encodeId=a15e153404383, content=<a href='/topic/show?id=6ea85e6117' target=_blank style='color:#2F92EE;'>#DC细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5761, encryptionId=6ea85e6117, topicName=DC细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=067412523287, createdName=zhangyxzsh, createdTime=Fri Mar 31 03:39:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183577, encodeId=da0e1835e7b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Wed Mar 29 19:33:51 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183564, encodeId=85811835640f, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Mar 29 19:28:48 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1348956, encodeId=6713134895620, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Mar 31 03:39:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534043, encodeId=a15e153404383, content=<a href='/topic/show?id=6ea85e6117' target=_blank style='color:#2F92EE;'>#DC细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5761, encryptionId=6ea85e6117, topicName=DC细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=067412523287, createdName=zhangyxzsh, createdTime=Fri Mar 31 03:39:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183577, encodeId=da0e1835e7b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Wed Mar 29 19:33:51 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183564, encodeId=85811835640f, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Mar 29 19:28:48 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-03-29 lecoo

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1348956, encodeId=6713134895620, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Mar 31 03:39:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534043, encodeId=a15e153404383, content=<a href='/topic/show?id=6ea85e6117' target=_blank style='color:#2F92EE;'>#DC细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5761, encryptionId=6ea85e6117, topicName=DC细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=067412523287, createdName=zhangyxzsh, createdTime=Fri Mar 31 03:39:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183577, encodeId=da0e1835e7b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Wed Mar 29 19:33:51 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183564, encodeId=85811835640f, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Mar 29 19:28:48 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-03-29 卡圣

    谢谢分享,学习了。

    0

相关资讯

肺癌靶向基因疗法的临床试验研究

辛辛那提大学(UC)医学院的研究人员正在招募患者进行临床试验,研究已经进行手术的早期肺癌患者的靶向基因疗法。

中国肺癌治疗迈入新时代

“肺癌是世界范围内癌症导致死亡的首要原因,中国是肺癌的高发地区。” 中国临床肿瘤学会(CSCO)理事长、广东省肺癌研究所所长吴一龙教授指出,2012年数据显示,我国每年发病人数约65万,死亡人数高达59万。2016年,我国肺癌发病达73万例,其发展形式十分迅猛。 1、吸烟是肺癌首要危险因素 吴一龙教授表示,吸烟是肺癌最显着的危险因素。有人质疑,吸烟与肺癌不是因果关系,而是伴随关系。但是,实验表

Chin J Oncol :精准医学助力肺癌转向慢性病

肺癌是我国发病率最高的恶性肿瘤,也是恶性肿瘤死因之首。目前,我国每年新发肺癌约50万,到2025年预计每年将有100万新发肺癌患者。近30年来,我国肺癌死亡率上升了465%。近年,非小细胞肺癌(NSCLC)分子病理诊断指导下的靶向治疗取得了巨大的进步,已成为临床标准治疗的一部分。然而,靶向治疗同时面临着获得性耐药等诸多问题。对于肿瘤治疗,真正实现精准医学仍然任重道远。现就肺癌的精准治疗进行阐述

专访张艰教授:EGFR—TKI的优势促成EGFR突变的晚期非小细胞肺癌患者具有更好的疗效、更少的不良反应

2017年新版基本医保药品目录于不久前更新,较2009年版目录增加了339个药品,增幅达15.4%,引发广泛影响。同时,还有一些药品被列为“拟谈判药品范围”如非小细胞肺癌(NSCLC)小分子靶向药物厄洛替尼等。近期,我们对多位专家进行专访,探讨了肺癌治疗现状、精准医学时代靶向治疗的疗效和安全性特点,并提出了靶向药物纳入医保的期待。本文总结第四军医大学西京医院呼吸内科张艰教授主要观点与读者分享。

Thorax:放射学模型对肺癌的筛查诊断哪个更好?

低剂量计算机断层扫描(LDCT)肺癌筛查相关的高假阳性(FP)扫描率导致许多不必要的随访检查和危害。“阳性”扫描的定义可以影响FP的概率和筛选性能。近期,一项发表在杂志Thorax上的研究探讨了肺成像报告和数据系统(肺-RADS)标准,PanCan结节恶性概率模型以及不同结节大小的阈值(≥4mm,≥6mm,≥8mm)对原始诊断准确性和筛查性能的影响,并将其与原始定义(国家肺癌筛查试验(NLST)标

晚期非小细胞肺癌各种治疗方案汇总及常见问题

2017.2版中,免疫药物——PD1抑制剂Keytruda被FDA批准,用于一线治疗(新诊断的癌症患者,首先接受的治疗)!Keytruda一线并不适用于所有肺癌,目前只针对“PD-L1高表达”,“无EGFR或ALK突变”的“非小细胞肺癌”。随着免疫疗法加入,非小细胞肺癌一线治疗用药将越来越精确:a.有EGFR,ALK等主流突变,考虑优先使用靶向药物(EGFR-易瑞沙、特罗凯、AZD9291等,AL